Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
About BYD & DENZA Benelux BYD & DENZA Benelux is the National Sales Company (NSC) responsible for the Benelux region (Belgium, Netherlands, and Luxembourg) and is part of BYD Europe and BYD Company Ltd., a China-based